Ileostomy - Stoma
Conditions
Keywords
probiotics, microbiota, ileostoma
Brief summary
To determine the small intestinal microbiota response in humans to dietary interventions for two consecutive weeks, and to relate this to parameters of intestinal barrier function and immune and metabolic responses in blood, as functional outcome parameters of host physiology
Interventions
DIETARY_SUPPLEMENTProbiotic 1
Fresh fermented dairy drink containing yoghurt ferments
DIETARY_SUPPLEMENTProbiotic 2
Fresh fermented dairy drink containing probiotic strain
DIETARY_SUPPLEMENTPlacebo
Acidified dairy drink without ferments
Sponsors
Maastricht University Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* • Ileostomy installed at least 3 years prior to participation * Free of any complications originating from the colectomy procedure for at least 1 yr prior to participation, with the exception of possible skin irritation at the location of the stoma * BMI from 18 till 28 kg/m2 * Age from 18 till 70 years * Available for entire study protocol. * For female: If of child bearing potential, female subjects must be using or complying with methods of contraception (such as oral birth control pills, intra-uterine device, double barrier methods (like condoms and spermicide, etc.)
Exclusion criteria
* • History of cardiovascular, respiratory, urogenital, hepatic, haematological / immunologic, HEENT (head, ears, eyes, nose, throat), dermatological/connective tissue, musculoskeletal, metabolic/nutritional, endocrine, neurological diseases, allergy, laboratory assessments which might limit participation in or completion of the study protocol, and/or major surgery with the exception of total colectomy, hysterectomy and/or appendectomy. * Subject with known lactose intolerance or with known or suspected allergy or hypersensitivity to any component of the study product(s) (milk protein for example) + sucrose + rhamnose * Severe gastrointestinal symptoms. In case of mild gastrointestinal symptoms, the principal investigator and the medically responsible MD will judge eligibility to participate. * Removal of more than 15 cm of the ileum during or at any moment after the colectomy procedure * Abdominal surgery interfering with gastrointestinal function, upon judgment of the principal investigator and the medically responsible MD * Use of medication, including proton pump inhibitors, non-steroidal anti-inflammatory drugs interfering with endpoints (but except oral contraceptives), within 14 days prior to and during participation. * Consumption of any probiotic or prebiotic supplements or pre- and probiotics containing food products, investigational drugs or participation in any scientific intervention study which may interfere with this study (to be decided by the principal investigator), in the 4 weeks prior to the study and during study participation (E4 PreProbiotics). * Use of antibiotics in the 4 weeks prior to the start of study and during study participation * Prohibited use of pro-, pre- or synbiotics during study period and three months prior to start of study. A list with forbidden products will be provided' * History of any side effects towards intake of pro- or prebiotic supplements of any kind.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Temporal microbial composition and activity in the small intestine in ileal effluent | 2 weeks intervention | The microbiome activity will be determined as a function of the diet by double strand cDNA production and random sequencing of mRNA enriched fractions of total effluent RNA obtained from the effluent samples at the start and end of each intervention period. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Gene transcription response in blood by transcriptome patterns. | 2 weeks intervention | Transcriptome patterns will be determined in peripheral blood mononuclear cells obtained from blood samples from the participating ileostoma patients |
| The levels of a panel of peripheral blood biomarkers related to immune, metabolic and hormonal status | 2 weeks intervention | A panel of biomarkers will be determined in peripheral blood obtained at the start and end of the intervention periods |
| The level of whole blood immune responsiveness to a panel of standardized stimuli ex vivo | 2 weeks intervention | Peripheral whole blood immune responsiveness towards a subset of bacterial immune-stimuli will be assessed using the standardized truculture system |
| Morning urine metabolome profiles | 2 weeks intervention | The principal analytical methodology employed is mass-spectrometry profiling and can commonly provide reliable quantifications of more than 400 named-metabolites in different body-fluid samples. |
| Small intestinal permeability by a multi sugar test (urinary recovery of test sugars) | 2 weeks intervention | — |
| The relative survival of bacterial strains (colony forming unit enumeration on semi-selective culture plates) | 2 weeks intervention | — |
| Short chain fatty acid profiles in ileal effluent | 2 weeks intervention | — |
| Number of participants with Gastrointestinal symptoms by Visual Analogue Scales | 2 weeks intervention | — |
| Occurrence and severity of treatment related adverse events | 2 weeks intervention | — |
| Peripheral blood metabolome profiles | 2 weeks intervention | The principal analytical methodology employed is mass-spectrometry profiling and can commonly provide reliable quantifications of more than 400 named-metabolites in different body-fluid samples. |
Countries
Netherlands
Outcome results
None listed